Actively Recruiting
Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis
Led by Cure 51 · Updated on 2023-12-07
1020
Participants Needed
1
Research Sites
234 weeks
Total Duration
On this page
Sponsors
C
Cure 51
Lead Sponsor
G
Gustave Roussy, Cancer Campus, Grand Paris
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a retrospective, exploratory, multi-center, translational, 3 cohorts case control matched study conducted in patients harboring a solid tumor with poor prognosis who presented a long-term (case) and standard (standard) survival. Patients with: * Cohort A: metastatic pancreatic ductal adenocarcinoma * Cohort B: glioblastoma IDHwt * Cohort C: extensive small cell lung cancer This research aims to integrate data generated from clinical records, imaging, multi-omics and bioinformatics approaches to discriminate case and control and then to identify new therapeutic targets. Analyses will be performed depending on the tumor samples available with at least 3 omics levels and according to scientific advances; genomic, epigenomic, proteomics, metabolomics, transcriptomic, microbiomic.
CONDITIONS
Official Title
Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patient (18 years or older at diagnosis)
- Diagnosed with metastatic pancreatic ductal adenocarcinoma, glioblastoma IDH wildtype, or extensive small cell lung cancer
- Long-term survival of at least 5 years from stage IV diagnosis for pancreatic ductal adenocarcinoma and small cell lung cancer, or at least 3 years for glioblastoma IDH wildtype
- Availability of at least one tumor block sample of sufficient quality and quantity for multi-omic analyses
- Any treatment prior to sample acquisition must be reported (all treatments accepted, including standard and targeted therapies)
- Samples should be at least 5 years old for pancreatic ductal adenocarcinoma and small cell lung cancer, and at least 3 years old for glioblastoma IDH wildtype
- Control group patients must be paired with long-term survivors and have death or median overall survival within 10% variation as reported in pivotal clinical trials
- Control group must have at least one tumor sample of sufficient quality and quantity for multi-omic analyses
- Control group treatments prior to sample acquisition must be reported (treatment-naive samples preferred, all treatments accepted)
You will not qualify if you...
- Younger than 18 years at diagnosis
- Hematological malignancies or solid tumors not included in the specified tumor types
- Tumor sample unavailable or not meeting quality requirements for multi-omic analyses
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Gustave Roussy Cancer Campus, Grand Paris
Villejuif, France, 94805
Actively Recruiting
Research Team
W
Wolikow Nicolas, Master
CONTACT
S
Simon Istolainen, Master
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here